Home | Publications | Drug Discovery place holder
place holder place holder

Drug Discovery

Genomics World Markets


Publication Date   May 2008
Publisher   TriMark Publications
Product Type   Report
Pages   160
ISBN Number   TMRGEN05-0921
Product Code   TRI005
Ask a question about this product?

Price £2,280.00

approximately: $3,400 | €2,716

Summary


Genomics is transforming the pharmaceutical industry. Companies are moving from drug discovery and development based on medicinal chemistry to the design of drugs based on information provided by genomics. Virtually all of the major pharmaceutical houses have either formed partnerships with genomics firms that began to emerge in the early 1990s or have created in house genomics divisions.

The aim of this study is to provide in depth information on the developing market for genomics products and services. The report will include detailed market analyses and discussions of industry trends in order to assess the impact of genomics on the current and emerging pharmaceutical and diagnostic markets. Forecasts and trends were developed from interviews with industry sources, as well as from an assessment of available and emerging technologies.

The report focuses on how researchers are applying new genomic approaches to drug discovery and development, and on how these technologies can be used most effectively and in a high throughput capacity. Case studies analyzing particular applications of genomic technologies to specific disease related research are provided, and future trends and developments are forecasted. Information to prepare this study was derived from interviews with product managers, marketing strategists, research executives and others. These individuals are employed at leading genomics firms or in pharmaceutical and biotechnology companies that either contract with these firms or have developed in house genomics capabilities.

Content


  • 1. Introduction
    • 1.1 Statement of Report
    • 1.2 Objectives and Goals of Study
    • 1.3 Methodology
    • 1.4 Information Sources
    • 1.5 Executive Summary
      • 1.5.1 Market Drivers
      • 1.5.2 Market Restraints
      • 1.5.3 Market Size and Growth Projections
    • 1.6 What Is A Gene?
    • 1.7 Gene Expression
    • 1.8 Genetic Variability
    • 1.9 Sequence Variability
    • 1.10 Expression Variability
    • 1.11 Opportunities Arising from Genetic Variability
    • 1.12 The Human Genome Project (Hgp)
    • 1.13 Gene Databases
    • 1.14 Resequencing
      • 1.14.1 Frozen in Time
      • 1.14.2 A Stepwise Approach
    • 1.15 The Role of Rnai in Drug Target Validation
    • 1.16 DNA Tags
  • 2. Genomics Technology and Industry
    • 2.1 The Biotechnology Industry
    • 2.2 The Development of A Genomics Market
      • 2.2.1 Market Size and Growth Projections
      • 2.2.2 The U.S. Genomics Market
    • 2.3 Biochips
    • 2.4 Bioinformatics
    • 2.5 Disease Targets
    • 2.6 Functional Genomics
    • 2.7 Gene Sequencing
      • 2.7.1 Gene Sequence Variation Detection
    • 2.8 Comparative Genomics
    • 2.9 Genome Database Arrays
    • 2.10 High-Throughput Genomics
    • 2.11 Lab-on-A-Chip
      • 2.11.1 Features of Labchip Systems
      • 2.11.2 Key Benefits of Labchip Systems
    • 2.12 High-Throughput Instrumentation
      • 2.12.1 Automated DNA Sequencing
      • 2.12.2 Application of High-Throughput DNA Sequencing to Sage Analysis
      • 2.12.3 Rna Expression Profiling Using DNA Microarrays
    • 2.13 Pharmacogenomics
    • 2.14 Probe Array
      • 2.14.1 Gene Expression Monitoring Arrays
      • 2.14.2 DNA Analysis Arrays
    • 2.15 Proteomics
    • 2.16 Sequencing
    • 2.17 Single-Nucleotide Polymorphism (Snp)
    • 2.18 Structural Genomics
    • 2.19 Photolithography
    • 2.20 Instrumentation
  • 3. How Genomics Is Revolutionizing Healthcare
    • 3.1 Pharmaceutical Applications
      • 3.1.1 Drug Discovery and Development
    • 3.2 Diagnostics
      • 3.2.1 Genome Screening by Comparative Genomic Hybridization
      • 3.2.2 Microchip Technology and Diagnostics
    • 3.3 Toxicogenomics
    • 3.4 The Market for DNA Microarrays
    • 3.5 DNA Chip Technology Competition
    • 3.6 Expression Profiling
    • 3.7 Gene Sequencing
      • 3.7.1 Advantages of Chip Array Technology
    • 3.8 Applied Markets for Genomics
    • 3.9 Genomics and Big Pharma
    • 3.10 The Snp Consortium
    • 3.11 Genomics Companies and Biopharmaceutical Companies
    • 3.12 Cancer Markets
    • 3.13 Agricultural Markets
      • 3.13.1 Plant Genetics
      • 3.13.2 Food Processing
      • 3.13.3 Animal Husbandry
  • 4. Proprietary Applications and Patents
    • 4.1 What Is Patentable?
    • 4.2 Patents and Litigation
  • 5. Business Analysis
    • 5.1 Facilitate and Capitalize on The Convergence of Gene Expression Analysis and Proteomics
    • 5.2 Competition
    • 5.3 Market Opportunities for Functional Genomics
    • 5.4 The Genomics Industry Is Highly Competitive
    • 5.5 The Overview for Drug Makers
    • 5.6 First-Generation Biotech
    • 5.7 The Second-Generation Genomics Companies
    • 5.8 Strategic Alliances
    • 5.9 Genomic Business Acquisitions, Mergers and Partnering
  • 6. Genomics Company Profiles
    • 6.1 Aclara Biosciences, Inc
      • 6.1.1 Business Strategy
    • 6.2 Affymetrix, Inc
      • 6.2.1 Business Strategy
      • 6.2.2 Gene Expression Monitoring
      • 6.2.3 Collaborative Partners
      • 6.2.4 Gene Expression Monitoring Collaborations
      • 6.2.5 DNA Analysis Collaborations
      • 6.2.6 Molecular Diagnostics Collaborations
      • 6.2.7 Other Collaborations
      • 6.2.8 Technology Licensees
    • 6.3 Agilent Technologies, Inc
    • 6.4 Applied Biosystems Group
    • 6.5 Bayer, Ag
    • 6.6 Clinical Micro Sensors
    • 6.7 Celera Genomics
    • 6.8 Curagen Corporation
      • 6.8.1 Business Strategy
      • 6.8.2 Discovery
      • 6.8.3 Preclinical
      • 6.8.4 Clinical
      • 6.8.5 Strategic Alliances
    • 6.9 Diversa Corporation, Inc
    • 6.10 Gene Logic, Inc
    • 6.11 Ge Healthcare
    • 6.12 Illumina, Inc
      • 6.12.1 Alliances
      • 6.12.2 Life Science Alliances
    • 6.13 Luminex Corporation
      • 6.13.1 Instruments
      • 6.13.2 Consumables
    • 6.14 Nanogen, Inc
      • 6.14.1 Business Overview
    • 6.15 Orchid Biosciences, Inc
      • 6.15.1 Products
      • 6.15.2 Services
    • 6.16 Sequenom, Inc
    • 6.17 Research Genetics
    • 6.18 Caliper Lifesciences
      • 6.18.1 Business Overview
      • 6.18.2 Corporate Strategy
      • 6.18.3 Leading Products
    • 6.19 Genentech, Inc./Genomic Solutions, Inc
      • 6.19.1 Business Overview
      • 6.19.2 Product Information
      • 6.19.3 Corporate Strategy
      • 6.19.4 Leading Products
    • 6.20 Harvard Bioscience, Inc
    • 6.21 Human Genome Sciences, Inc
      • 6.21.1 Business Overview
      • 6.21.2 Corporate Strategy
      • 6.21.3 Leading Products
    • 6.22 Millennium Pharmaceuticals, Inc
      • 6.22.1 Business Overview
      • 6.22.2 Leading Products
    • 6.23 Myriad Genetics, Inc
      • 6.23.1 Business Overview
      • 6.23.2 Corporate Strategy
      • 6.23.3 Leading Product Candidates
    • 6.24 Nanogen, Inc
      • 6.24.1 Business Overview
      • 6.24.2 Leading Product Candidates
    • 6.25 Perkinelmer, Inc
      • 6.25.1 Business Overview
      • 6.25.2 Leading Products
    • 6.26 Brief Profiles of Other Selected Genomics Firms
      • 6.26.1 Aber Genomic Computing
      • 6.26.2 Decode Genetics, Inc
      • 6.26.3 Molecular Devices Corporation
      • 6.26.4 Spotfire, Inc
      • 6.26.5 454 Life Sciences
  • 7. Genomics Challenges and Growth Factors
    • 7.1 Market Drivers
      • 7.1.1 Product Pipeline: Need for More Drug Candidates
      • 7.1.2 Need for Increased Research and Development Productivity
    • 7.2 Genomics Market Bottlenecks
      • 7.2.1 Cost Constraints
      • 7.2.2 Technical Hurdles
    • 7.3 Strategic Recommendations
      • 7.3.1 Market Opportunities
    • 7.4 Key Trends of Recent Mergers and Acquisition Deals
    • 7.5 Chemogenomics
    • 7.6 Pharmacogenomics
    • 7.7 Biomarkers
    • 7.8 Additional Genomics Market Opportunities
  • 8. Bioinformatics
    • 8.1 Types of Data and Bioinformatics Applications
      • 8.1.1 Validated Core Modeling Technology
      • 8.1.2 Broad Applicability
      • 8.1.3 Data Management Compliant with Industry Standards
      • 8.1.4 Open Architecture
      • 8.1.5 Ease of Use
      • 8.1.6 Increased Access
    • 8.2 Functions of Informatics Software
      • 8.2.1 Data Management
      • 8.2.2 Transform Data into Knowledge
      • 8.2.3 Collaboration among Researchers
      • 8.2.4 Interface for Online Data Sources
    • 8.3 Target Markets for Informatics Software
      • 8.3.1 Pharmaceutical Companies
      • 8.3.2 Biotechnology Companies
      • 8.3.3 Academic and Government Research Institutions
      • 8.3.4 Agricultural, Environmental and Industrial Biotechnology Companies
    • 8.4 Products of Bioinformatics
      • 8.4.1 Sequences and Structure of Genes and Proteins
      • 8.4.2 3-D Molecular Structures
      • 8.4.3 Genome Structures and Functions
      • 8.4.4 Bibliographic Data
    • 8.5 Bioinformatics Processes
    • 8.6 Informatics Tools and Functionalities
      • 8.6.1 Sequence to Structure
      • 8.6.2 Lead Identification and Optimization
      • 8.6.3 Development and Formulation
      • 8.6.4 Improving Materials and Processes in The Chemicals Industry
      • 8.6.5 Other Materials-Based Industries
    • 8.7 Role of Bioinformatics in The Value Chain
    • 8.8 Bioinformatics Market Segments
      • 8.8.1 Database
      • 8.8.2 Hardware
      • 8.8.3 Software
      • 8.8.4 Bioinformatics Services
    • 8.9 Bioinformatics Business Models
      • 8.9.1 Changing Business Models
      • 8.9.2 Selected Business Strategies
        • Glossary
    • Index of Figures
    • Figure 1: Global Biotechnology Industry
    • Figure 2: Role of Bioinformatics in The Biotechnology Value Chain
    • Ndex of Tables
    • Table 1: Top U.S. Biotechnology Companies by Market Capitalization
    • Table 2: Top U.S. Biotechnology Companies in Genomic Segment
    • Table 3: Total Equity Raised by Biotech Companies by Year, 1990-2003
    • Table 4: Global Biotechnology Industry Major Segments 2005
    • Table 5: Genomics Sector Market Size, 20012010
    • Table 6: Biochip Market Size
    • Table 7: Selected Competitors in The Biochip Markets
    • Table 8: Biochip Microarray Products
    • Table 9: Bioinformatics Tools
    • Table 10: The Worldwide Market for Bioinformatics, 2000-2010
    • Table 11: Selected Companies Building Advanced Integrated Platforms and Genomics Databases
    • Table 12: Companies Using New Genomic Tools
    • Table 13:Detection Technology Companies for Genomics
    • Table 14: Spotting Technology Suppliers
    • Table 15: Robotics or "lab-on-A-Chip" Market Sector
    • Table 16: Key High-Throughput and Systemic Approaches for Genomic Analysis
    • Table 17: Pharmacogenomics Segment Players
    • Table 18: The World Wide Market for Pharmacogenomics through 2008
    • Table 19: Competitors in The Snp-Genotyping Segment
    • Table 20: Scanning and Detection Technology Suppliers
    • Table 21: Genomics Pharmaceutical Market Sector Leaders
    • Table 22: Companies Focused on The Genomics Biotechnology Market Sector
    • Table 23: Companies Focused on The Genomics Diagnostic Market Sector
    • Table 24: The Worldwide Market for Genomics-Based Diagnostics
    • Table 25: Applied Markets for Genomics
    • Table 26: DNA Testing Segment Players
    • Table 27: Opportunities for Molecular-Targeting Therapeutics for Cancer
    • Table 28: The Clinical Research Organizations (Cro) Sector
    • Table 29: Emerging Companies in The Anti-Cancer Sector
    • Table 30: First Generation Biotech Companies Financial Performance Market, 2003
    • Table 31: Biotech Companies Transitioned to Drug Companies Market, 2003
    • Table 32: Selected Strategic Alliances of Genomic Companies
    • Table 33: Commercial Organizations with Significant Sequencing Capacity
    • Table 34: Summary of Selected Affymetrix Expression Profiling Customers
    • Table 35: Curagen's Proprietary Technologies
    • Table 36: Data Source and Bioinformatic Investigations
    • Table 37: Bioinformatics Activities, Subactivities and Key Players